LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 10.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,858 shares of the medical instruments supplier's stock after selling 6,355 shares during the period. Nuveen Asset Management LLC owned about 0.24% of LeMaitre Vascular worth $4,962,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its stake in LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 293 shares during the period. CBIZ Investment Advisory Services LLC boosted its holdings in LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 117 shares in the last quarter. KBC Group NV grew its stake in LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after acquiring an additional 410 shares during the period. Huntington National Bank increased its holdings in shares of LeMaitre Vascular by 64.9% during the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after acquiring an additional 455 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of LeMaitre Vascular during the fourth quarter worth approximately $150,000. Institutional investors and hedge funds own 84.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LMAT. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital boosted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price for the company. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $97.83.

LeMaitre Vascular Trading Down 0.6%

LMAT stock traded down $0.47 on Wednesday, hitting $82.40. The company had a trading volume of 9,404 shares, compared to its average volume of 168,232. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 45.02, a P/E/G ratio of 2.22 and a beta of 0.86. The stock's 50-day simple moving average is $83.75 and its 200 day simple moving average is $91.44. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company's revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 EPS. Research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.97%. LeMaitre Vascular's dividend payout ratio is currently 40.40%.

Insider Activity at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 76,868 shares of LeMaitre Vascular stock in a transaction on Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the sale, the chief executive officer now directly owns 1,796,783 shares in the company, valued at approximately $154,146,013.57. This trade represents a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 102,009 shares of company stock valued at $8,721,836. 9.50% of the stock is owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.